Clinical Trial Update: Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel and Cisplatin on Clinical Trial GOG-172 [NA]

View source ↗

Summary

Withdrawn clinical trial update for GOG-172 evaluating paclitaxel plus cisplatin in stage III ovarian cancer. No results or economic outcomes were reported due …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Ovarian Cancer | NA | Status: WITHDRAWN